Rituximab and Tacrolimus drugs in primary membranous nephropathy
- Conditions
- Health Condition 1: N042- Nephrotic syndrome with diffuse membranous glomerulonephritis
- Registration Number
- CTRI/2018/10/015976
- Lead Sponsor
- IPGMER SSKM hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Biopsy proven PMN of age group 18-70 years,
2.Fulfilling the criteria for initiation of immunosuppression- Urinary protein excretion persistently exceeds4 g/d AND remains at over 50% of the baseline value, AND does not show progressive decline, during antihypertensive and antiproteinuric therapy during an observation period of at least 6 months or Severe disabling or life threatening symptoms related to the nephrotic syndrome.
3.SCr has risen by 30% or more within 6 to 12 months from the time of diagnosis but the eGFR is not less than 25â??30 ml/min per 1.73m2 AND this change is not explained by superimposed complications.
1.Patients with active infection.
2.Diabetes mellitus.
3.Hepatitis B/C or human immunodeficiency virus infection.
4.Superimposed any other liver disease.
5.Neoplasia.
6.Chronic Diarrhoea.
7.Pregnancy.
8.Patients not willing for contraception.
9.Previous therapy with Prednisolone, MMF,CSA within 4 months and alkylating agents within 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method